CL2009000609A1 - Triphasic combined pharmaceutical product with 24 dosage units, where the amount of drospirenone during the three phases is constant and the amount of 17 beta-estradiol increases from 1 mg to 2 mg, in addition to 4 dosage units of placebo or without units of dosage; pharmaceutical kit. - Google Patents

Triphasic combined pharmaceutical product with 24 dosage units, where the amount of drospirenone during the three phases is constant and the amount of 17 beta-estradiol increases from 1 mg to 2 mg, in addition to 4 dosage units of placebo or without units of dosage; pharmaceutical kit.

Info

Publication number
CL2009000609A1
CL2009000609A1 CL2009000609A CL2009000609A CL2009000609A1 CL 2009000609 A1 CL2009000609 A1 CL 2009000609A1 CL 2009000609 A CL2009000609 A CL 2009000609A CL 2009000609 A CL2009000609 A CL 2009000609A CL 2009000609 A1 CL2009000609 A1 CL 2009000609A1
Authority
CL
Chile
Prior art keywords
dosage
units
amount
dosage units
triphasic
Prior art date
Application number
CL2009000609A
Other languages
Spanish (es)
Inventor
Rolf Schurmann Dr
Vladimir Hanes Dr
Bernd Dusterberg Dr
Joachim Marr Dr
Hartmut Blode Dr
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41065592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009000609(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CL2009000609A1 publication Critical patent/CL2009000609A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Producto farmacéutico que comprende drospiredona y 17beta-estradiol, combinación que contiene este producto y kit que contiene esta combinación.Pharmaceutical product comprising drospiredone and 17beta-estradiol, combination contained in this product and kit containing this combination.

CL2009000609A 2008-03-10 2009-03-13 Triphasic combined pharmaceutical product with 24 dosage units, where the amount of drospirenone during the three phases is constant and the amount of 17 beta-estradiol increases from 1 mg to 2 mg, in addition to 4 dosage units of placebo or without units of dosage; pharmaceutical kit. CL2009000609A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3528508P 2008-03-10 2008-03-10
US3612908P 2008-03-13 2008-03-13
US4041008P 2008-03-28 2008-03-28

Publications (1)

Publication Number Publication Date
CL2009000609A1 true CL2009000609A1 (en) 2010-03-26

Family

ID=41065592

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000609A CL2009000609A1 (en) 2008-03-10 2009-03-13 Triphasic combined pharmaceutical product with 24 dosage units, where the amount of drospirenone during the three phases is constant and the amount of 17 beta-estradiol increases from 1 mg to 2 mg, in addition to 4 dosage units of placebo or without units of dosage; pharmaceutical kit.

Country Status (3)

Country Link
CL (1) CL2009000609A1 (en)
TW (1) TW200942242A (en)
WO (1) WO2009112231A2 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1598069B1 (en) * 1999-08-31 2009-04-22 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
CN1878558A (en) * 2003-11-14 2006-12-13 沃纳奇尔科特公司 Gradient estrogen contraceptives
UY29527A1 (en) * 2005-05-13 2006-12-29 Schering Ag PHARMACCUTIC COMPOSITION CONTAINING GESTRGENS AND / OR ESTRNGENS AND 5-METHYL - (6S) - TETRHYDROPHOLATE.

Also Published As

Publication number Publication date
TW200942242A (en) 2009-10-16
WO2009112231A2 (en) 2009-09-17
WO2009112231A3 (en) 2010-10-21

Similar Documents

Publication Publication Date Title
CL2008001721A1 (en) Compounds derived from 17-beta-cyano-18 alpha-homo-19-nor-androst-4-eno; presenting gestagenic and antimineralcorticoid activity; pharmaceutical composition; and use in the treatment of pre-peri-and postmenopausal disorders and premenstrual disorders.
ECSP13012618A (en) DERIVATIVES OF 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINA SUBSTITUTED WITH AMINOALCOHOLES THAT ARE USEFUL TO TREAT HYPERPROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
BRPI0415639A (en) once daily controlled release oxycodone oral dosage forms
CL2008001303A1 (en) Compounds derived from heterocycles, gamma secretase modulators; pharmaceutical composition; pharmaceutical kit; and use in the treatment of Alzheimer's.
CR10838A (en) DERIVATIVES OF 2,3-DIHYDROIMIDAZOL [1,2-C] QUINAZOLINE SUBSTITUTED, USEFUL IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
CL2008001123A1 (en) Compounds derived from lipoic acid; pharmaceutical formulation comprising it; and use in the treatment of cancer.
CL2012003026A1 (en) Pharmaceutical composition comprising pioglitazone and linagliptin; preparation procedure; Use in the treatment of type 2 diabetes or obesity.
CL2008001373A1 (en) Compounds derived from substituted phenylamino-benzene; Preparation method; pharmaceutical composition; farm kit; and use of said compounds in the treatment of cancer.
MY143795A (en) Tetrahydropyridoindole derivatives
CL2013000266A1 (en) Compounds derived from cis-tetrahydrospiro (cyclohexan-1,1'-pyrido [3,4-b] indole) -4-amine; combination and pharmaceutical formulation; and use in the treatment of neuropathic and / or chronic pain.
PA8720801A1 (en) NEW THERAPEUTIC COMBINATIONS FOR THE TREATMENT OF DEPRESSION
EA201290381A1 (en) APPLICATION OF CONTENTS OF OLEGEL TRITERPENE FOR THE HEALING OF THE RAS
EA201001283A1 (en) COMBINATION OF VITAMIN D AND 25-HYDROXIVITAMINE D3
UY31403A1 (en) "NOVEDOUS DERIVATIVES OF ({((3-Methylphenyl) -2H-TETRAZOL-5-IL) -ETOXI} -4H-1,2,4-TRIAZOL-3-IL), PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND MEDICAL USE OF THE SAME" .
CL2012001940A1 (en) Compositions comprising extracts of andrographis paniculata combined with extracts of ginkgo biloba complexed with phospholipids; and its use in the preparation of a medicament for the treatment of Alzheimer's and multiple sclerosis.
DE602007002553D1 (en) THEIR USE FOR THE PREPARATION OF A THERAPEUTIC AND / OR PROPHYLACTICALLY ACTIVE PHARMACEUTICAL COMPOSITION
NZ596683A (en) A pharmaceutical, dermatological, nutritional or cosmetic composition for combating the immunosuppressive action of aggressive agents on the skin using a mixture of catechin and quercetin
EP2392322A3 (en) Dosing regimes for trans-clomiphene
AR072951A1 (en) USE OF DRONEDARONE OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THIS, FOR THE PREPARATION OF A MEDICINAL PRODUCT TO REGULATE THE LEVEL OF POTASSIUM IN THE BLOOD
CL2012003265A1 (en) Tamarind seed polysaccharide for use in the treatment of infectious diseases; pharmaceutical and / or anti-inflammatory dermocosmetic composition containing said polysaccharide; use of a tamarind seed polysaccharide.
TR201004464A2 (en) Formulation for bone resorption.
EA200701923A1 (en) DRUG FORM FOR THE ORAL ADMINISTRATION OF VITAMIN
CL2008001719A1 (en) Compounds derived from [1,10] -phenanthroline; preparation procedure; pharmaceutical composition; and use in the treatment of neurodegenerative or hematological diseases.
CL2009000294A1 (en) Compounds derived from aryl methylidene heterocycles; pharmaceutical composition comprising them; and use in the treatment of neuropathic pain and inflammation.
CL2008002060A1 (en) Compounds derived from sulfonamide, inhibitors of beta amyloid production; Preparation method; pharmaceutical composition; pharmaceutical kit; and use in the treatment of diseases such as Alzheimer's, amyloid angiopathy, down syndrome, among others.